Top Industry Leaders in the Costochondritis Market
Latest Costochondritis Companies Updates:
Johnson & Johnson's Ethicon unit launched the Enseal X1 Straight Jaw Tissue Sealer in April 2022. While not directly applicable to Costochondritis, this advanced device highlights J&J's continued investment in minimally invasive surgical tools, which could potentially be used in future surgical treatments for severe Costochondritis cases.
Stryker received FDA approval for BoTOX® for Glabellar Lines in August 2023. Again, not directly related to Costochondritis, this approval showcases the expanding applications of BoTOX® for pain management, potentially opening doors for future research on its use for Costochondritis-related pain.
List of Costochondritis companies in the market:
- KemPharm
- GlaxoSmithKline plc
- Biovail Corporation
- Aurobindo Pharma
- Pfizer Inc
- Recro Pharma Inc
- LUPIN
- Bausch Health Companies Inc
- Avenue Therapeutics